Rayyan Fahad Hamoud Altemani
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rayyan Fahad Hamoud Altemani has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Alabbasi
Ministry of Health, Jeddah, Saudi Arabia
2 shared publications - Mohammed Sayes
Department of Medicine, University of Utah, Salt Lake City, USA
2 shared publications - Muhanad Alzahrani
Department of Medicine, University of Maryland Medical Center, Baltimore, USA
2 shared publications - Ziyad Alzahrani
College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia
2 shared publications - Abdullah Almosa
Intern, College of Medicine, Almaarefa University, Saudi Arabia
1 shared publication - Abeer Mohammed M. Al-Enezi
University of Tabuk, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 28 February 2026
- Published by Institute of Lifestyle Medicine in Journal of Lifestyle Medicine
- Vol. 16 (1) , 32-38
Accelerated Muscle Strength Decline and Reduced Lean Mass in Adults with Treated Inflammatory Bowel Disease: A NHANES Study
Muhanad Alzahrani, Abdullah Alabbasi, Mohammed Sayes, Rayyan Fahad Hamoud Altemani, Ziyad Alzahrani, Faris Sultan. JLM 2026;16:32-8. https://doi.org/10.15280/jlm.2026.16.1.32
- 28 February 2026
- Published by Institute of Lifestyle Medicine in Journal of Lifestyle Medicine
- Vol. 16 (1) , 32-38
Open AccessAccelerated Muscle Strength Decline and Reduced Lean Mass in Adults with Treated Inflammatory Bowel Disease: A NHANES Study
Muhanad Alzahrani, Abdullah Alabbasi, Mohammed Sayes, Rayyan Fahad Hamoud Altemani, Ziyad Alzahrani, Faris Sultan. JLM 2026;16:32-8. https://doi.org/10.15280/jlm.2026.16.1.32
- Open Access
- 2 January 2026
- Published by Wolters Kluwer Health in Indian Journal of Anaesthesia
- Vol. 70 (1) , 79-91
Safety and efficacy of remimazolam in general anaesthesia during laparoscopic cholecystectomy: A systematic review and meta-analysis of randomised controlled trials
Background and Aims: Laparoscopic cholecystectomy (LC) presents anaesthetic challenges such as haemodynamic instability and postoperative complications. Remimazolam (RMZ), a novel ultra-short acting benzodiazepine, has emerged as a promising alternative to the standard propofol, with a potentially superior safety profile. This study aimed to compare the efficacy and safety of RMZ with propofol for anaesthesia during LC. Methods: A systematic review and meta-analysis were conducted to synthesise evidence from randomised controlled trials (RCTs). A search of PubMed, Web of Science, Scopus, and Google Scholar through May 2025 was conducted. We pooled dichotomous outcomes using risk ratios (RRs) and continuous outcomes using mean differences (MDs), and 95% confidence intervals (CIs). Results: Six RCTs involving 452 patients were included in the analysis. Compared to the control group, RMZ was associated with a significantly longer anaesthesia onset time (MD: 13.26, 95% CI: 0.47, 26.05, P = 0.04), recovery time (MD: 2.72, 95% CI: 0.44, 5.01, P = 0.02), and postanaesthesia care unit (PACU) stay (MD: 5.54, 95% CI: 0.86, 10.22, P = 0.02). However, RMZ significantly reduced the incidence of injection pain (RR: 0.03, 95% CI: 0.01, 0.15, P < 0.001), and no significant differences were observed in surgery duration ( P = 0.30), extubation time ( P = 0.14), or the incidence of hypotension ( P = 0.15), bradycardia ( P = 0.13), or postoperative nausea and vomiting ( P = 0.67). Conclusion: With uncertain evidence, RMZ significantly prolonged anaesthesia onset time, recovery time, and time to PACU discharge compared to control in patients undergoing LC. Still, RMZ improved patient comfort through significantly decreased incidence of injection pain and is associated with a comparable haemodynamic safety profile to propofol.
- 2 January 2026
- Published by Wolters Kluwer Health in Indian Journal of Anaesthesia
- Vol. 70 (1) , 79-91
Open AccessSafety and efficacy of remimazolam in general anaesthesia during laparoscopic cholecystectomy: A systematic review and meta-analysis of randomised controlled trials
Background and Aims: Laparoscopic cholecystectomy (LC) presents anaesthetic challenges such as haemodynamic instability and postoperative complications. Remimazolam (RMZ), a novel ultra-short acting benzodiazepine, has emerged as a promising alternative to the standard propofol, with a potentially superior safety profile. This study aimed to compare the efficacy and safety of RMZ with propofol for anaesthesia during LC. Methods: A systematic review and meta-analysis were conducted to synthesise evidence from randomised controlled trials (RCTs). A search of PubMed, Web of Science, Scopus, and Google Scholar through May 2025 was conducted. We pooled dichotomous outcomes using risk ratios (RRs) and continuous outcomes using mean differences (MDs), and 95% confidence intervals (CIs). Results: Six RCTs involving 452 patients were included in the analysis. Compared to the control group, RMZ was associated with a significantly longer anaesthesia onset time (MD: 13.26, 95% CI: 0.47, 26.05, P = 0.04), recovery time (MD: 2.72, 95% CI: 0.44, 5.01, P = 0.02), and postanaesthesia care unit (PACU) stay (MD: 5.54, 95% CI: 0.86, 10.22, P = 0.02). However, RMZ significantly reduced the incidence of injection pain (RR: 0.03, 95% CI: 0.01, 0.15, P < 0.001), and no significant differences were observed in surgery duration ( P = 0.30), extubation time ( P = 0.14), or the incidence of hypotension ( P = 0.15), bradycardia ( P = 0.13), or postoperative nausea and vomiting ( P = 0.67). Conclusion: With uncertain evidence, RMZ significantly prolonged anaesthesia onset time, recovery time, and time to PACU discharge compared to control in patients undergoing LC. Still, RMZ improved patient comfort through significantly decreased incidence of injection pain and is associated with a comparable haemodynamic safety profile to propofol.
- 31 August 2021
- Published by Sciencedomain International in Journal of Pharmaceutical Research International
- Vol. 33 (42B) , 49-54
Cutaneous Disorders Due to Exposures to Marine Life: A Simple Review
Exposure to aquatic organisms includes a variety of clinical situations. Skin damage after exposure to the marine environment includes bacterial and fungal infections as well as damage caused by aquatic plants and protists. Aquatic skin diseases are various skin diseases found among swimmers, divers, fishermen and tourists participating in water activities. Some conditions are particularly relevant to fresh or salt water, while other conditions may occur in both environments at the same time. Injuries can be divided into several general categories. There may also be overlapping, non-infected mechanical damage, infection after mechanical damage, and mechanical damage accompanied by inoculation of poisons or substances with sensitizing properties. The clinical manifestations of skin diseases generally include erythema, blisters, urticaria, edema, scars, pigment changes and paresthesias. General management is achieved through the application of first aid as well as diagnostic imaging and tetanus prevention.
- 31 August 2021
- Published by Sciencedomain International in Journal of Pharmaceutical Research International
- Vol. 33 (42B) , 49-54
Cutaneous Disorders Due to Exposures to Marine Life: A Simple Review
Exposure to aquatic organisms includes a variety of clinical situations. Skin damage after exposure to the marine environment includes bacterial and fungal infections as well as damage caused by aquatic plants and protists. Aquatic skin diseases are various skin diseases found among swimmers, divers, fishermen and tourists participating in water activities. Some conditions are particularly relevant to fresh or salt water, while other conditions may occur in both environments at the same time. Injuries can be divided into several general categories. There may also be overlapping, non-infected mechanical damage, infection after mechanical damage, and mechanical damage accompanied by inoculation of poisons or substances with sensitizing properties. The clinical manifestations of skin diseases generally include erythema, blisters, urticaria, edema, scars, pigment changes and paresthesias. General management is achieved through the application of first aid as well as diagnostic imaging and tetanus prevention.